The Europe Human Organoids Market was valued at $301.3 Million in 2024 and projected to reach to $546.8 Million by 2029, representing a compound annual growth rate of 12.7%. Europe's human organoids market is positioned for sustained expansion, supported by robust regulatory frameworks, substantial public and private research funding, and a concentration of leading biotech companies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Germany dominates Europe's human organoids market with $183.9 million in 2024, driven by world-class biotech infrastructure and leading pharmaceutical R&D investments across regenerative medicine applications.
Europe's stringent regulatory frameworks and established approval pathways for organoid-based therapies provide competitive advantages, attracting major biotech investments and accelerating clinical translation across the region.
Europe's premier research institutions and collaborative networks foster innovation in organoid technology, with significant funding from Horizon Europe and national research programs supporting breakthrough discoveries.
Europe's human organoids market is projected to grow from $301.3 million in 2024 to $546.8 million by 2029, representing a 12.7% CAGR, reflecting strong demand for personalized medicine and disease modeling solutions.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DEVELOPMENTAL BIOLOGY (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 14.4% from 2024 to 2029 |
| Largest Segment | READY-TO-USE PRODUCTS (Type) |
| Market Size Base Year (Billions) | ~USD 1.19 (2024) |
| Revenue Forecast (Billions) | ~USD 2.33 (2029) |
| Segments Covered | Product, Type, Source, Culture Method, Disease Area, Application, End User |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 30.9 | 33 | 36 | 39.4 | 43.5 | 48.5 | 54.5 | 61.8 | 11.4 |
| CROS | 82.1 | 88.2 | 96.8 | 106.7 | 118.4 | 132.9 | 150.3 | 171.3 | 12.1 |
| OTHER END USERS | 9 | 9.6 | 10.3 | 11.2 | 12.2 | 13.5 | 15.1 | 16.9 | 10.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 131.1 | 143.9 | 158.3 | 176.6 | 198.2 | 225.1 | 257.5 | 296.8 | 13.4 |
| TOTAL | 253.1 | 274.6 | 301.3 | 333.9 | 372.3 | 419.9 | 477.3 | 546.8 | 12.7 |
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 6.5 | 6.8 | 7.2 | 7.8 | 8.4 | 9.2 | 10.1 | 11.3 | 9.3 |
| CROS | 16.1 | 17.1 | 18.4 | 20 | 21.9 | 24.2 | 26.9 | 30.2 | 10.4 |
| OTHER END USERS | 1.7 | 1.7 | 1.8 | 1.9 | 2.1 | 2.2 | 2.4 | 2.7 | 8.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 27.9 | 30 | 32.7 | 35.9 | 39.8 | 44.5 | 50.2 | 57 | 11.8 |
| TOTAL | 52.1 | 55.7 | 60.2 | 65.7 | 72.1 | 80.1 | 89.7 | 101.2 | 11 |
| Country | 2025 size (native) |
|---|---|
| Germany | USD 183.9 Million |
| UK | USD 105.9 Million |
| France | USD 32.8 Million |
| Italy | USD 17.5 Million |
| Spain | USD 10.3 Million |
| Rest Of Europe | USD 35.2 Million |
Europe's human organoids market was valued at $301.3 million in 2024 and is projected to grow to $546.8 million by 2029.
Europe's human organoids market is growing at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2029.
Growth in Europe is driven by strong government funding, advanced regulatory frameworks, collaborative research networks, and increasing investment in regenerative medicine and personalized medicine applications.
Europe's leading organoid research hubs include the United Kingdom, Germany, Switzerland, and the Netherlands, which host major biotech companies and research institutions.
Primary applications in Europe include disease modeling, drug testing, personalized medicine development, and regenerative medicine therapies across oncology, gastroenterology, and organ transplantation.
The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Thermo Fisher Scientific Inc. | Director of sales |
| Merck KGaA | Sales Executive |
Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.
Full forecast, segment splits, and company analysis for all Human Organoids Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report